ArticleDiscover oncology2025
CPZ promotes the proliferation of gastric cancer by activating the Wnt pathway through binding with DVL2.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundGastric cancer (GC) is one of the most prevalent and heterogeneous malignancies worldwide, with treatment outcomes often hindered by delayed diagnosis and limited therapeutic options. Consequently, identifying novel targets for GC diagnosis and treatment is of significant clinical relevance. This study investigated the role of CPZ in GC progression and explored its molecular mechanisms and potential as a prognostic marker and therapeutic target.
methodsBioinformatics analysis and clinical pathological evaluations were conducted to assess CPZ expression in GC and its correlation with clinical parameters. In vivo and in vitro experiments, including CCK8 proliferation assays, flow cytometry, and xenograft mouse models, were employed to confirm the impact of CPZ on GC malignancy. Potential molecular mechanisms through which CPZ regulates GC cell biological functions were identified and validated using immunoprecipitation mass spectrometry (IP-MS), co-immunoprecipitation (Co-IP), protein truncation assays, GST-pull down assays, and Western blotting. The CPZ inhibitor PF-573228 was identified through screening a small-molecule compound library.
resultsCPZ expression was significantly upregulated in GC (tumor tissues vs. normal tissues = 54.3% vs. 10.1%), correlating with unfavorable clinical pathological parameters and poor prognosis. CPZ directly interacts with DVL2 via its C-terminal domain (187-581aa). Its role in promoting tumorigenesis (both in vivo and in vitro) by fostering GC proliferation and regulation of cell cycle distribution is partially dependent on CPZ-DVL2 interaction, which activates the Wnt/β-catenin signaling pathway. PF-573228 specifically inhibits CPZ-mediated GC cell proliferation and tumor growth in mouse models (approximately fivefold compared to the control group).
conclusionThis study highlights the potential of CPZ as a novel biomarker and prognostic predictor for GC, while also elucidating its role in GC progression. The identification of PF-573228 as a specific inhibitor of CPZ provides a basis for the development of new therapeutic strategies for GC diagnosis and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.